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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the e#ectiveness of social network and social support interventions to support cardiac rehabilitation and secondary prevention
in the management of people with heart disease.
As a secondary  output of this review, and to assist in conceptualising future research focused on social network and social support
interventions, we aim to develop a logic model theorising the relationship between social networks or social support and heart disease
outcomes. We will draw on existing models of social support for health (e.g. Berkman 2000), as well as established approaches to theorising
and implementing behaviour change (e.g. Michie 2011).
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B A C K G R O U N D
Description of the condition
'Heart disease'  encompasses a range of disorders a#ecting the
heart, including: diseases of the heart blood vessels (coronary
heart disease (CHD)); heart rhythm problems (arrhythmias, such
as atrial fibrillation); heart infections; and congenital heart
defects. CHD is the most common type of heart disease; its
common symptoms are chest pain (angina) and heart attack
(myocardial infarction). Coronary heart disease may necessitate a
revascularisation procedure, and can lead to chronic heart failure.
Globally, cardiovascular diseases (CVD; heart and circulatory
diseases combined) contribute to 31% of all deaths, more than any
other cause (WHO 2017). Of the estimated 17.7 million deaths from
CVD in 2015, the most common cause (7.4 million) was CHD. Of 17
million premature deaths from non-communicable diseases in the
same year, 37% were caused by CVD (WHO 2017).
Cardiac rehabilitation (CR) programmes aim to go beyond
secondary prevention and address physical, mental, and social
factors, to support individuals to continue or resume their day-
to-day life following a cardiac event, diagnosis, or procedure
(BACPR 2017). CR programmes are widely o#ered, in line with
guidance in the UK and globally, to people with a number of
presentations of heart disease, and include various psychosocial,
educational, health behaviour change, and risk management
components (Dalal  2015  ). In this review, we will focus on heart
disease indications for which people in the United Kingdom
are typically referred for cardiac rehabilitation, namely: CHD
(including myocardial infarction, post-revascularisation, and stable
angina); chronic heart failure; atrial fibrillation; and following valve
replacement or repair procedures (BACPR 2017).
Description of the intervention
The impact on health behaviours of social networks, and the
social support communicated through them, has generated a vast
body of literature, grounded in sociological, anthropological, and
psychological theory (Berkman  2000). Interest has particularly
increased in recent times in relation to how the influence of social
networks might be harnessed in health interventions. Evidence
suggests that social network or social support interventions are
associated with positive outcomes in some health behaviours
(Hunter 2019). Social support or social network interventions
may have potential in rehabilitation or secondary prevention
programmes for CVD, since low levels of social support are
specifically associated with increased risk of CHD events (Lett
2005), and  social isolation and weak social networks have been
linked to poor outcomes for individuals with heart disease
(Heidari Gorji 2019). Contemporary technologies facilitate remote
provision or engendering of social support, for example the use of
social media, smart device applications (apps), video conferencing-
based interventions,  potentially broadening the scope of social
network interventions for health. As such, social network and social
support interventions may play an important role as an adjunct
to current evidence-based secondary prevention and rehabilitation
measures, in improving outcomes for people with CVD (Piepoli
2016).
The scope of this review includes interventions specifically
identified as ‘social network’ or ‘social support’ interventions.
Diversity in how these terms are understood and used means
conceptual clarity is essential. In this review, and following
Berkman  2000, we will use ‘social network’ to mean ‘the web
of social relationships that surrounds an individual and the
characteristics of those ties’ (e.g. family, friendship, or other social
groups); and ‘social support’ to mean one of the ‘mediating
pathways by which networks might influence health’, using
emotional, instrumental, appraisal, or informational means (e.g.
via peer-to-peer support, app-based support, dedicated online
groups). We will use ‘social network' or 'support intervention’ to
indicate interventions that explicitly aim to mobilise relationships
with partners, caregivers, friends, family members, or peer
supporters (e.g. others with the same condition), to improve health.
The review will include interventions that capitalise on social
networks or social support, which may be implemented
individually or in groups, and in a range of settings including
home, primary or secondary care, or remotely (by phone or online).
The review will include interventions which: aim to reduce social
isolation or improve connectedness, or both; use apps or social
media technologies to connect people with heart disease; or
use a formal component of Social Network Analysis (SNA); or a
combination. We do not intend to include studies where SNA has
been used in study methodology, but where the intervention itself
does not involve elements of social support, or where social media
platforms are used without an intended element of social support.
How the intervention might work
Social networks and social support may operate at a number
of levels to promote healthy behaviours, through mechanisms
including: reinforcement, encouragement, motivation, feedback,
empathy, role modelling, increased self-e#icacy, instrumental
support (i.e. practical help), emotional support, appraisal (e.g.
a#irmation), peer pressure for healthy behaviours, or access to
health information (Simpson 2015). Social support can be provided
by family, friends, peers or wider social networks, and members of
specific groups with a common behavioural goal (e.g. weight loss
groups). Social support is identified as a key component in both
initiating and sustaining behaviour change (Hunter 2019; Simpson
2011; Simpson 2020). Nevertheless, how social networks or social
support might improve outcomes for people with heart disease is
largely under-theorised.
The application of behaviour change theory in a di#erent health
context (weight loss) suggests a social network or social support
intervention can facilitate goal setting, action planning, problem
solving, support ongoing health goals, encourage self-monitoring,
and promote autonomy (Simpson 2020). They may o#er an
opportunity to enhance inclusion and accessibility for populations
who are less likely to engage in cardiac rehabilitation (CR), such
as women and people from black, Asian, and minority ethic
(BAME) groups (Dalal  2015  ). Contextual factors, which might
impact the feasibility and e#ectiveness of social network or
social support interventions might include: the availability of
friends, family, or peers to o#er support; characteristics of the
person o#ering support; characteristics of the social network
or relationship; degree of integration within a social network;
access to resources (e.g. time to exercise, healthy food, etc.);
socioeconomic factors; and everyday barriers to, and facilitators of
participation (Berkman 2000; Simpson 2011).
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Why it is important to do this review
Heart disease is a global public health concern associated with
significant health, social, and economic burden in developed and
developing countries alike. Social isolation and low social support
 have been shown to be common in people with cardiac disorders,
and associated with poor outcomes, including increased risk of
hospital readmission (Heidari  Gorji  2019; Lett 2005; Mookadam
2004). More broadly, there is growing interest in understanding the
impact of social network and social support-based interventions
on health-related behaviour (Berkman  2000). Interventions with
social support components are not well understood, and there is no
current consensus on how they might be most e#ectively provided.
The addition of social network or social support interventions
may have a role in enhancing the e#ectiveness of secondary
prevention and CR. In the UK and globally, CR is widely
o#ered for the conditions noted above, and includes various
psychosocial, educational, health behaviour change, and risk
management components (Dalal  2015  ). However, uptake is
suboptimal and inequitable – due to a combination of factors
including accessibility, dislike of centre-based classes, an absence
of both uniform referral processes and physician familiarity,
and availability – with disproportionately lower referral and
uptake in women, and people in lower socioeconomic, or BAME
groups (Dalal  2015  ).   In some contexts, up-front costs to
users of CR and inconsistent reimbursement also act as barriers
(Babu 2016). Lower cost, non-centre-based CR can improve uptake
(Dalal  2019). However, depending on the mode of delivery,
it may risk limiting face-to-face interaction with others with
similar conditions. Including social network or social support
components to CR programmes may address this limitation.
Guidelines on CR specifically highlight the importance of improving
outcomes by using existing social support, and encouraging new
social connections where available and appropriate (BACPR 2017;
SIGN 2017). They also highlight the potential to capitalise on
new technologies (Piepoli 2016). As a result of the COVID-19
pandemic, the need for secondary prevention and e#ective models
of CR, based outside  traditional clinical settings – including
in the home and using remote delivery –  has become acute,
as has the need to minimise social isolation. The current
context highlights challenges, opportunities, and the demand
for innovative approaches, including social network and social
support interventions (Dalal 2020; de Sire 2020).
By conducting this review, we aim to contribute to a body of
knowledge on the potential benefits of interventions that use
or facilitate social networks or social support for people with
heart disease, and to inform future research and intervention
development.
O B J E C T I V E S
To assess the e#ectiveness of social network and social support
interventions to support cardiac rehabilitation and secondary
prevention in the management of people with heart disease.
As a secondary  output of this review, and to assist in
conceptualising future research focused on social network and
social support interventions, we aim to develop a logic model
theorising the relationship between social networks or  social
support and heart disease outcomes. We will draw on existing
models of social support for health (e.g. Berkman 2000), as well as
established approaches to theorising and implementing behaviour
change (e.g. Michie 2011).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (with individual
participant allocation, cluster-allocation, or cross-over design) of a
social network or social support intervention for people with heart
disease. We will include trials regardless of their duration of follow-
up, and we will include studies reported as full text, those published
as abstract only, and unpublished data.
Types of participants
We will include all individuals, aged ≥ 18 years with physician-
diagnosed: chronic heart failure (hereaOer ‘heart failure’), coronary
heart disease (myocardial infarction (MI), post-revascularisation,
or stable angina), atrial fibrillation, or post-valve replacement or
repair procedures.
If a trial contains a mixed population (i.e. individuals with diagnoses
other than heart disease) we will (1) assess whether subgroup
results for heart disease are reported. If not, we will contact the trial
authors. If results are not available, we will (2) include all the trial
data as long as people with heart disease make up 50% or more of
the total trial population. We will carry out a sensitivity analysis to
assess the impact of including studies with mixed populations, if we
are unable to get the subgroup data from trialists.
We will exclude trials if they do not focus (at least 50% of
trial population) on participants with heart failure, coronary
heart disease (MI, post-revascularisation, or stable angina), atrial
fibrillation, or post-valve replacement or repair procedures.
Types of interventions
We will include all interventions that explicitly include a
component of social network or social support, i.e. interventions
that involve partners, caregivers, friends, family members, peer or
lay supporters (e.g. others with the same condition). Interventions
may be implemented individually or in groups, including those
using applications (apps) or other social media technologies
to connect people with heart disease. We will not include
interventions where the only form of social support is interaction
with a healthcare or social work professional (even where framed
explicitly as ‘social support’). We will consider all social network
or social support interventions, delivered either alone or as part of
a wider cardiac rehabilitation (CR) programme (e.g. with exercise
or educational components), i.e. trial comparison of CR plus
social network or social support intervention versus CR alone.
The intervention may be based in any setting, including the
participant’s home, the community, or in primary or secondary
care, providing the above criteria are met. Interventions may be
supervised or unsupervised, and single or multi-component.
The review will characterise the nature of the intervention (e.g.
duration, intensity, mode of delivery) for each included study. If
there are su#icient studies, we will explore the impact of these
intervention variations on participant outcomes, using approaches
that include meta-regression.
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Both the intervention and control group participants will receive
usual medical care as reported by the study. Usual care typically
comprises secondary prevention measures, including regular
check-ups, drug treatment (e.g. antihypertensive or lipid-lowering
drugs), and advice for a healthy and active lifestyle (e.g. diet,
smoking, and physical activity). Some people may also receive a
programme of CR. This review will include studies that explicitly
assesses the impact of the addition of a social network or social
support intervention to a usual care comparator that could include
secondary prevention alone, or secondary prevention and CR.
We recognise that trial participants may be receiving co-
interventions (e.g. antihypertensive, lipid-lowering therapy), and
we anticipate that the receipt of such co-interventions will be
balanced across intervention and control arms.
Types of outcome measures
Reporting one or more of the outcomes listed here in the trial is
not an inclusion criterion for the review. When a published report
does not appear to report one of these outcomes, we will access
the trial protocol and contact the trial authors to ascertain whether
the outcomes were measured but not reported. We will include
relevant trials that measured these outcomes but did not report the
data at all, or not in a usable format, as part of the narrative in the
review.
We will extract primary and secondary outcomes at all reported
follow-up points, categorised as short-term (12 months or less) or
long-term (more than 12 months). As long-term follow-up (more
than 12 months) is our period of most interest – due to its usefulness
in informing policy decisions – we will seek to include the longest
follow-up period in the ‘Summary of findings’ table, depending on
the duration of follow-up in the included trials.
Primary outcomes
1. All-cause mortality
2. Cardiovascular-related mortality
3. All-cause hospital admission (number of events)
4. All-cause hospital admission (number of participants with at
least one event)
5. Cardiovascular-related hospital admission (number of events)
6. Cardiovascular-related hospital admission (number of
participants with at least one event)
7. Health-related quality of life (HRQoL) assessed by validated
generic (e.g. Short-Form 36 (SF-36)) or disease specific (e.g.
HeartQoL) measures
Secondary outcomes
1. Psychological well-being (validated measures of depression and
anxiety e.g. HADS)
2. Heart disease risk factors:
a. smoking,
b. blood pressure (systolic),
c. blood pressure (diastolic),
d. LDL,
e. HDL, and
f. total cholesterol
3. Myocardial infarction (number of events)
4. Myocardial infarction (number of participants with at least one
event)
5. Revascularisation (number of events)
6. Revascularisation (number of participants with at least one
event)
7. Physical activity behaviour (validated self-report measures of
physical activity e.g. IPAQ-SF, GPAQ, and EHIS-PAQ, or objective
measures like accelerometry)
8. Return to work or full-time education
9. Social isolation and connectedness using validated outcomes
(e.g. Multidimensional Scale of Perceived Social Support
(MSPSS), Personal Social Capital Scale (PSCS))
10.Participant satisfaction (validated measures, e.g. Patient
Satisfaction Questionnaire)
11.Adverse events: we will include any reports of adverse events
related to the intervention, by number of events of each type.
We define adverse events as any untoward occurrence related
to the intervention (e.g. psychological distress associated with
use of the intervention).   We will classify adverse events as
‘serious’ (any occurrence that can result in life-threatening
situations, disability, or death, or requires hospitalisation of any
duration or ‘non-serious’ (European Commission 2011).
We will not include cost as a specific outcome. However,  should
such data be available, we will comment on them in a narrative
format.
Search methods for identification of studies
Electronic searches
We will identify trials through systematic searches of the following
bibliographic databases:
• Cochrane Central Register of Controlled Trials (CENTRAL) in the
Cochrane Library;
• MEDLINE Ovid (1946 onwards);
• Embase Ovid (1980 onwards);
• Web of Science Core Collection.
We will adapt the preliminary search strategy for MEDLINE Ovid to
use in the other databases (Appendix 1). We will apply the Cochrane
sensitivity and precision-maximising RCT filter to MEDLINE Ovid,
and adaptations of it to the other databases, except CENTRAL
(Lefebvre 2019).
We will conduct a search of the US National Institutes of Health
Ongoing Trials Register ClinicalTrials.gov (www.ClinicalTrials.gov),
and the World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch/) for ongoing or
unpublished trials.
We will search all databases from their inception to the present,
and impose no restriction on language of publication or publication
status. We will not perform a separate search for adverse e#ects of
social network or social support interventions for people with heart
disease.
Searching other resources
We will check reference lists of all included studies and any relevant
systematic reviews identified, for additional references to trials. We
will also examine any relevant retraction statements and errata for
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included studies. We will contact the main authors of studies and
experts in the field to ask for any missed, unreported, or ongoing
trials.
Data collection and analysis
Selection of studies
Two review authors (CP and SS) will independently screen the
titles and abstracts of all records we identify as a result of the
search, and code them as 'retrieve' (eligible, or potentially eligible,
or unclear), or 'do not retrieve'. If there are any disagreements, they
will ask a third review author to arbitrate (RST or SAS). We will
retrieve the full-text study reports and publication, and two review
authors (CP and SS) will independently screen the full-text report,
identify studies for inclusion, and identify and record reasons for
excluding the ineligible studies. We will resolve any disagreement
through discussion, or if required, we will consult a third person
(RST or SAS). We will identify and exclude duplicates, and collate
multiple reports of the same study, so that each study rather than
each report is the unit of interest in the review. We will record the
selection process in su#icient detail to complete a PRISMA flow
diagram and 'Characteristics of excluded studies' table (Liberati
2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review. One review author (CP and SS) will extract the following
study characteristics from included studies.
1. Methods: study design, total duration of study, number of study
centres and location, study setting, and date of study
2. Participants: N randomised, N lost to follow-up or withdrawn, N
analysed, mean age, age range, gender, heart disease diagnosis,
inclusion criteria, and exclusion criteria
3. Interventions: intervention, comparison, and co-interventions.
The intervention description will include coding of the nature
of intervention delivery categorised, for example by: behaviour
change techniques used; dose; type of support provided;
who provides support (e.g. partners, family, peer supporters);
whether face-to-face or remote, delivered one-to-one or in a
group, supervised or unsupervised, etc.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
5. Notes: funding for trial, and notable conflicts of interest of trial
authors
Two review authors (CP and SS) will independently extract outcome
data from included studies. We will resolve disagreements by
consensus, or by involving a third person (SAS or RST). One review
author (CP) will transfer data into RevManWeb  (Review Manager
2020). We will double-check that data are entered correctly by
comparing the data presented in the systematic review with the
data extraction form. A second review author (SS) will spot-check
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (MHB and either SS or CP) will independently
assess risk of bias for each study using the second version of
the Cochrane 'Risk of bias' tool (RoB 2), outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2019c).
We will resolve any disagreements by discussion, or by involving
another review author (RST or SAS). The e#ect of interest we will
assess is the e#ect of assignment to the intervention. The outcomes
we will assess are those included in the 'Summary of findings'
table. We will use the 'RoB 2' tool to manage the assessment of bias.
We will assess the risk of bias of specific results of a trial according
to the following domains:
1. bias arising from the randomisation process;
2. bias due to deviations from intended interventions;
3. bias due to missing outcome data;
4. bias in measurement of the outcome; and
5. bias in selection of the reported result.
For cluster-RCTs we will add an additional domain, 1b, ‘Bias arising
from the timing of identification and recruitment of participants’,
and use the signalling questions from the archived version of
the 'ROB 2' tool. For cross-over RCTs, we will use the signalling
questions specific to cross-over trials from the archived version of
the 'ROB 2' tool for domain 2, and for signalling question 3.2 of
domain 3.
We will assess risk of bias in each domain. An algorithm (decision
tree) using a series of signalling questions and answers (yes,
probably yes, no information, probably no, no) will determine risk
of bias (low risk, some concerns, and high risk).
Our analysis of bias due to deviations from intended interventions,
will assess the e#ect of assignment to the intervention at baseline,
sometimes known as the ‘intention-to-treat e#ect’.
We will classify each potential source of bias (as low, high, or some
concerns), and provide a quotation from the study report, and a
justification for our judgement, recording these details in the Excel
'ROB 2' tool. We will summarise our 'Risk of bias' judgements across
di#erent studies, for each of the domains listed. Where information
on risk of bias relates to unpublished data or correspondence with
a trial author, we will note this in the Excel 'ROB 2' tool.
When analysing treatment e#ects, we will consider the risk of bias
for the studies that contribute to that outcome. In the Results
section of the review, we will present visual summaries of the 'ROB
2' judgments for each outcome and study, and narrative summaries
of the 'Risk of bias' judgments for each domain within each
outcome. We will provide full details of the consensus decisions
on risk of bias for each signalling question, study, and outcome,
together with supporting quotations, in an online repository. We
will determine the overall risk of bias for each study, according to
the criteria for reaching overall 'Risk of bias' judgments, set out in
Table 8.2.b in the Handbook (Higgins 2019c).
Measures of treatment eect
We will analyse dichotomous data as risk ratios (RR) with 95%
confidence intervals (CI), and continuous data as mean di#erence
(MD) with 95% confidence intervals. For any outcomes that are
measured by studies in a variety of ways, we will either analyse
these outcomes separately, or we will use the standardised mean
di#erence (SMD) with 95% confidence intervals as a summary
statistic. We will interpret the SMD using the two approaches
recommended in the Handbook. First, for all mean pooled SMD,
we will apply the rule of thumb, based on Cohen's e#ect sizes, as
advised in the Handbook: i.e. 0.2 represents a small e#ect, 0.5 a
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moderate e#ect, and 0.8 a large e#ect. In addition, we will convert
the SMD to the original scale units, by multiplying the pooled
mean SMD by a standard deviation (SD) from a particular trial. We
will enter data presented as a scale with a consistent direction
of e#ect. We will describe skewed data, reported as medians and
interquartile ranges, in a narrative format.
Unit of analysis issues
In accordance with Section 16.4 of the Cochrane Handbook for
Systematic Reviews of Interventions, we will aim to include data
from both periods of any cross-over trials identified, assuming (i)
there was a wash-out period considered long enough to reduce
carry-over, (ii) no irreversible events, such as mortality occurred,
and (iii) appropriate statistical approaches were used (Higgins
2019a).
We will use multiple time points from individual trials; to define
completely separate pooled analyses of outcomes (e.g. HRQoL less
than six months; HRQoL between six and 12 months, etc.). This
approach will avoid the situation in which the same data appear
more than once in the same analysis.
We will adjust cluster-RCT sample sizes or standard errors using the
methods outlined in the Cochrane Handbook for Systematic Reviews
of Interventions, using an estimate of the intra-cluster correlation
co-e#icient (ICC) derived from the trial, from a similar trial, or
from a study of a similar population. If we use ICCs from other
sources, we will report this result, and conduct sensitivity analyses
to investigate the e#ect of variation in the ICC.
If a trial has more than two control or intervention arms
(e.g. cardiac rehabilitation and  social support (intervention arm)
versus cardiac rehabilitation alone (control arm 1), versus no
intervention (control arm 2)), we will include two interventions
versus control comparisons, by dividing the number randomised
to the intervention group for each comparison in half to obtain the
denominator for data analysis; the mean and standard deviation for
the intervention group remain unchanged for both comparisons.
We will also acknowledge heterogeneity in the randomisation unit,
and conduct a subgroup analysis to investigate the e#ects of the
randomisation unit.
Dealing with missing data
We will contact investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data,
where possible (e.g. when a study is identified as abstract only).
Where possible, we will use RevManWeb  calculator to calculate
missing standard deviations, using other data from the trial, such as
confidence intervals, based on methods outlined in the Handbook
(Higgins 2019b).
Assessment of heterogeneity
We will inspect forest plots visually to consider the direction
and magnitude of e#ects, and the degree of overlap between
confidence intervals. We will use the I2 statistic to measure
heterogeneity among the trials in each analysis, but acknowledge
that there is substantial uncertainty in the value of I2 when there is
only a small number of studies. We will also consider the P value
from the Chi2 test, i.e. the confidence interval for I2. If we identify
considerable heterogeneity, i.e. I2 values of 75% to 100%, we will
report it and explore possible causes by pre-specified subgroup
analysis. We will also explore clinical heterogeneity of included
studies qualitatively, by comparing the characteristics of included
studies.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine
a funnel plot, and use the Egger test, to explore possible small study
biases for the primary outcomes (Egger 1997).
Data synthesis
We will include all eligible studies in the primary analysis. We will
undertake meta-analyses only where this is meaningful, i.e. if the
interventions, participants, and outcomes are similar enough for
pooling to make sense.
We will express dichotomous outcomes for each comparison as risk
ratios (RR). We will express continuous data as mean di#erence
(MD) with 95% CI; or, when an outcome is measured and reported in
more than one way (e.g. HRQoL), as standardised mean di#erence
(SMD) with 95% CI. We will enter data presented as a scale with a
consistent direction of e#ect.
Given the likely clinical heterogeneity in trials we will include in
this review, where it is judged appropriate to formally pool studies,
we will initially use a random-e#ects meta-analysis model. For
all meta-analyses, we will also use a fixed-e#ects model, because
of the tendency of smaller trials (which are more susceptible
to publication bias) to be over-weighted with a random-e#ects
analysis; we will comment when there are di#erences between
results from fixed-e#ect and random-e#ects models (Heran 2008a;
Heran 2008b). We will complete data synthesis and analyses
using RevMan Web (Review Manager 2020). We will conduct meta-
regression analysis using the 'metareg' command in Stata version
16.060 (Stata).
To refine the proposed theory of change, and to assess the
plausibility of the theorised causal pathways, we will map the
results of the data synthesis against our initial logic model.
Subgroup analysis and investigation of heterogeneity
We anticipate the size of e#ect for some outcomes will be
related to the length of the follow-up. Therefore, we will present
separate meta-analyses of each outcome according to length of
follow-up: i.e. we will pool studies with  short-term follow-up (12
months or less), and long-term follow-up (more than 12 months),
based on the  longest follow-up reported. We will also try to
undertake univariate meta-regression, to explore heterogeneity
and examine potential treatment e#ect modifiers. For the primary
outcomes, we will aim to test whether a relationship exists between
e#ect estimates and the following study characteristics:
1. Risk of bias i.e. high risk or high risk/some concerns versus low
risk of bias
2. Type of intervention (e.g. social network or social support only
versus multi-component intervention (categorical variable))
3. Duration of social network or social support intervention
(continuous variable)
4. Type of population (e.g. acute event or procedure (post-
MI, revascularisation, valve surgery) versus chronic condition
(e.g. heart failure, atrial fibrillation, stable angina; (categorical
variable))
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5. Nature of intervention delivery (e.g. home versus centre-based;
supervised versus unsupervised, remote (phone or online)
versus face-to-face; trained or qualified practitioner versus lay
person delivery; one-to-one versus group; (categorical variable))
6. Study location (low- or middle-income countries (LMIC) or high-
income countries (HIC), as per Organisation for Economic Co-
operation and Development (OECD) classification; (categorical
variable))
7. Mean age of participants (continuous variable)
8. Percentage of male and female participants (continuous
variable)
Given the anticipated small ratio of trials to covariates, we will
limit meta-regression to univariate analysis, and to situations in
which 10 or more trials are available (Higgins 2019a). We anticipate
a small number of included studies; therefore, we recognise that
it is unlikely we will be able to conduct a meta-regression or a
stratified meta-analysis. If reported by individual included studies,
we will extract results of subgroup analyses, including participant-
level subgroup analyses; for example, if a trial reports whether
there was a di#erence in the e#ectiveness of interventions between
males and females. If applicable, we will use the formal test for
subgroup di#erences in RevMan Web, and base our interpretation
on this (Review Manager 2020).
Sensitivity analysis
If applicable, we will conduct sensitivity analyses  to assess
the impact of including studies with mixed populations (where
subgroup data are not available from the trialists), and to
investigate the e#ect of variation in the intra-cluster correlation co-
e#icient (if ICCs from other sources are used).
Summary of findings and assessment of the certainty of the
evidence
We will create a 'Summary of findings' table with our primary
outcomes:
1. All-cause mortality
2. Cardiovascular-related mortality
3. All-cause hospital admission (number of events)
4. All-cause hospital admission (number of participants with at
least one event)
5. Cardiovascular-related hospital admission (number of events)
6. Cardiovascular-related hospital admission (number of
participants with at least one event)
7. Health-related quality of life (HRQoL) assessed by validated
generic (e.g. Short-Form 36) or disease specific (e.g. HeartQoL)
measures
8. Adverse events
We will use the five GRADE considerations (risk of bias, consistency
of e#ect, imprecision, indirectness, and publication bias) to
assess the certainty  of a body of evidence as it relates to the
studies that contribute data to the meta-analyses for the pre-
specified outcomes. We use the overall 'RoB 2' judgment for each
outcome as part of the GRADE assessment. We will use methods
and recommendations described in Chapter 14 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2019), and use GRADEpro soOware (GRADEpro GDT).  We will
justify all decisions to downgrade the certainty of  the evidence
using footnotes and we will make comments to aid reader's
understanding of the review where necessary.
Long-term follow-up (> 12 months) is our follow-up period of most
interest, because it is useful to inform policy decisions. Therefore,
we will include long-term follow-up (>12 months) for each of the
specified outcomes in the ’Summary of findings’ table.
Two review authors (CP and SS) will independently make
judgements about the certainty of the evidence, with
disagreements resolved by discussion, or by involving a third
review author (RST or SAS). They will justify, and document their
judgments, and incorporate them into the reporting of results for
each outcome.
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A P P E N D I C E S
Appendix 1. Preliminary MEDLINE Ovid search strategy
1 exp Coronary Disease/ (218087)
2 ((coronary or heart) adj2 disease*).tw. (259374)
3 CHD.tw. (25075)
4 CAD.tw. (39184)
5 exp Heart Failure/ (122114)
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6 heart failure.tw. (166963)
7 HF.tw. (45717)
8 exp Myocardial Infarction/ (175710)
9 myocardial infarct*.tw. (194875)
10 MI.tw. (47541)
11 heart attack*.tw. (5541)
12 Revasculari?ation*.tw. (57793)
13 exp Coronary Artery Bypass/ (52897)
14 coronary artery bypass.tw. (40608)
15 CABG.tw. (17997)
16 exp Percutaneous Coronary Intervention/ (54071)
17 percutaneous coronary intervention.tw. (30820)
18 PCI.tw. (25920)
19 exp Angioplasty/ (61553)
20 angioplast*.tw. (43465)
21 Angina, Stable/ (1351)
22 Stable angina.tw. (8058)
23 Atrial Fibrillation/ (55636)
24 atrial fibrillation*.tw. (70435)
25 AF.tw. (40412)
26 (valve adj2 (replace* or repair*)).tw. (39487)
27 or/1-26 (976828)
28 Social Networking/ (3529)
29 social network*.tw. (17198)
30 exp social support/ (71403)
31 social support.tw. (38511)
32 Partner*.tw. (174598)
33 Caregivers/ (36925)
34 Caregiver*.tw. (64512)
35 Friends/ (5213)
36 Friend*.tw. (88578)
37 Family/ (76201)
38 (family or families).tw. (948756)
39 Relatives.tw. (58102)
40 (spouse* or wife or wives or husband or husbands or partner*).tw. (201765)
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41 supporter*.tw. (3166)
42 peer group/ (20653)
43 (peer or peers).tw. (92508)
44 Social Media/ (8137)
45 (social media or facebook or twitter).tw. (14503)
46 Mobile Applications/ (6149)
47 ((mobile or electronic) adj2 (app or apps or application*)).tw. (8155)
48 or/28-47 (1450097)
49 27 and 48 (27663)
50 randomized controlled trial.pt. (512300)
51 controlled clinical trial.pt. (93824)
52 randomized.ab. (491073)
53 placebo.ab. (210651)
54 clinical trials as topic.sh. (192774)
55 randomly.ab. (340120)
56 trial.ti. (224310)
57 50 or 51 or 52 or 53 or 54 or 55 or 56 (1310665)
58 exp animals/ not humans.sh. (4730611)
59 57 not 58 (1206602)
60 49 and 59 (2383)
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